Close
Achema middle east
swop processing & packaging

BTG receives US Voraxaze approval

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

No New Drug Submissions by the FDA With Shutdown in Place

The Food and Drug Administration (FDA), which is already...

How to Tell if Your Loved One is Developing an Addiction

Watching a loved one change in ways you do...

The Future of Balding Treatments: What’s New in 2025

Are you balding or thinning out on top? It...

UK-based pharmaceutical company BTG has received US Food and Drug Adminsitration (FDA) approval for its Voraxaze medication, which is used to treat patients suffering from toxic levels of methotrexate due to kidney failure.

The basis of the approval was due to results found in a study of 22 patients, which saw methotrexate levels fall below the critical threshold within 15 minutes of treatment, staying below that level for eight days afterwards. Of the 22 patients, ten achieved the standard and Voraxaze eliminated 95% of methotrexate in all patients in the study.

Voraxaze works by breaking down methotrexate into inactive metabolities, which are then removed from the body using organs other than the kidney. Prolonged exposure to high levels of methotrexate can result in kidney and liver damage, damage to the lining of the intestine and, in severe cases, death due to low blood counts.

BTG acquired Voraxaze through its 2008 merger with Protherics, and the drug represents the first treatment that the company has received approval for within the US.

 

Latest stories

Related stories

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

No New Drug Submissions by the FDA With Shutdown in Place

The Food and Drug Administration (FDA), which is already...

How to Tell if Your Loved One is Developing an Addiction

Watching a loved one change in ways you do...

The Future of Balding Treatments: What’s New in 2025

Are you balding or thinning out on top? It...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »